This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Teva Pharmaceutical Industries Ltd.
Drug Names(s): COP-1, copolymer-1, glatiramer acetate
Description: Copaxone (Glatiramer acetate) is an approved drug for the treatment of multiple sclerosis. It is a synthetic analog of myelin basic protein, a component of the myelin that insulates nerve fibers in the brain and spinal cord. It binds to MHC molecules on T cells, preventing native myelin antigens from binding to these T cells and consequent attacks on myelin-covered nerve fibers.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Teva and Aventis and Teva Marion Partners
Teva Marion Partners (TMP) was formed in 1995 as an equally owned marketing partnership between Teva and Aventis Pharmaceuticals, to promote Copaxone in North America.
In February 2001, under the agreement signed by Teva and Aventis, TMP will become a wholly owned subsidiary of Teva and will be renamed Teva Neuroscience. Aventis will continue to distribute Copaxone in North America while keeping the existing mutual economic benefits.
The marketing of injectable Copaxone in Europe will continue under the current strategic alliance agreement between Teva and Aventis. However, Teva has reserved the right, under certain conditions, to reacquire the marketing and distribution rights to the injectable formulation of Copaxone at such time as the oral formulation reaches the European market.
Aventis and Sanofi and Sanofi-Aventis
Sanofi-aventis was formed in 2004...See full deal structure in Biomedtracker
Partners: Sanofi Takeda Pharmaceutical Company Ltd
Additional information available to subscribers only: